INBRAIN Neuroelectronics Partners with Mayo Clinic to Advance its Graphene-Based Medical Technology

by Chema Arcos

The ICN2 spin-off will collaborate with this prestigious US medical foundation and hospital to further develop its graphene Brain-Computer Interfaces (BCI) for the treatment of neurological disorders.

INBRAIN Neuroelectronics, a spin-off company from ICN2, ICREA and CSIC, has signed a collaboration agreement with Mayo Clinic, one of the world’s leading medical institutions. The partnership aims to exchange technical expertise and further advance the development and clinical evaluation of INBRAIN’s pioneering graphene-based medical technologies.

Last year, the company began clinical trials in human patients to assess the safety of its graphene-based brain-computer interfaces, designed to support the treatment of neurological disorders. This first study, conducted in Manchester and co-led by ICREA Prof. Kostas Kostarelos, head of the ICN2 Nanomedicine Lab, has already yielded positive results, confirming the safety of the technology.

At the same time, INBRAIN announced plans to open locations in Boston and on the U.S. West Coast, while keeping its headquarters and R&D department in Barcelona. This strategy will facilitate the achievement of high-quality clinical results, accelerate the commercialisation of its technology, and scale up manufacturing processes for therapeutic applications.